Our June issue of Pharmaceutical Executive offers a uniquely diverse range of coverage and voices—a "sum-of-its-parts" balance that's not always easy to pull off.
In our June issue of Pharmaceutical Executive, we present an interesting dichotomy of coverage across three of our feature stories. It’s a combination and balance that isn’t always easy to achieve, but when it does, it’s pretty cool. A thought-provoking cocktail, if you will. And it usually occurs organically, when planning, timing, execution, and even a drop of happenstance (see Mark Cuban) all fall into place.
Our June issue is a perfect example, and we hope you find the coverage a little extra special. We first offer an exclusive interview with the aforementioned Cuban, where the Dallas Mavericks owner (bracing for Boston in the NBA Finals as of this writing), “Shark Tank” star, and, as of early 2022, in the direct-to-consumer pharmacy game, dishes on the problems—and his solutions—to the complex and always highly-charged pharmaceutical pricing apparatus in the US. The interview and article materialized after Group Social Media Editor Miranda Schmalfuhs noticed that Cuban followed our sister publication, Pharmaceutical Commerce, on X. She reached out to the biz giant, querying his interest in discussing the evolution of his popular Cost Plus Drug Company in disrupting the systems in place determining prescription drug cost. The rest is history.
As you can imagine, in classic Cuban style, he’s honest and direct. And, as far as his company’s mission—providing a transparent, affordable Rx buying option (with 2,200 drugs available and growing)—he’s focused on the moment.
Two additional June coverage pieces feature themes and people on the other end of the healthcare and motivation spectrums—the manufacturer and developer sides. But those, too, are each diverse from the other. One is our Pharma 50 report, presenting our annual rankings of the top 50 biopharma companies based on prescription drug sales, and the other an executive profile of Craig Tooman, CEO of the clinical-stage biotech Silence Therapeutics, who discusses his company’s work advancing hopeful next-generation treatments based on the idea of “silencing” or suppressing genes.
So a little old with a little new. The commercial jockeying of Big Pharma and the innovation impact of emerging biotech. Power and promise.
We hope all our coverage this month delivers some valuable and useful food for thought. As always, thanks for reading.
Mike Hennessy Jr. is President and CEO of MJH Life Sciences
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.